Ceryvyn Therapeutics Limited (ASX:CYV)
0.0100
0.00 (0.00%)
Oct 29, 2026, 4:10 PM AEDT
Ceryvyn Therapeutics Revenue
In the fiscal year ending June 30, 2026, Ceryvyn Therapeutics had annual revenue of 1.00K AUD, down -99.56%. That makes Ceryvyn Therapeutics the 47,692nd largest company in the world by revenue and 1,551st in Australia.
Revenue
1.00K
Revenue Growth
-99.56%
P/S Ratio
13,679.78
Revenue / Employee
30.30
Employees
33
Market Cap
13.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.00K | -227.00K | -99.56% |
| Jun 30, 2025 | 228.00K | -164.69K | -41.94% |
| Jun 30, 2024 | 392.69K | -186.19K | -32.16% |
| Jun 30, 2023 | 578.88K | 290.04K | 100.42% |
| Jun 30, 2022 | 288.84K | 161.37K | 126.61% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 12.87M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
Ceryvyn Therapeutics News
- 17 hours ago - Ceryvyn Therapeutics Earnings release: Q1 2027 - Filings
- 1 month ago - Ceryvyn Therapeutics Annual report: H2 2026 - Filings
- 4 months ago - Ceryvyn Therapeutics Transcript: Investor update - Transcripts
- 4 months ago - Ceryvyn Therapeutics Slides: Investor update - Filings
- 4 months ago - Ceryvyn Therapeutics Slides: Investor presentation - Filings
- 6 months ago - Ceryvyn Therapeutics Earnings release: Q3 2026 - Filings
- 8 months ago - Ceryvyn Therapeutics Quarterly report: H1 2026 - Filings
- 10 months ago - Ceryvyn Therapeutics Slides: Corporate presentation - Filings